Dublin-based drug maker Shire said to value Baxalta at $32bn

Baxalta jumped to a four-and-a-half-month high yesterday on reports that rival drug maker Shire — the US firm formally based in Ireland — is in advanced talks to acquire it.

Dublin-based drug maker Shire said to value Baxalta at $32bn

Baxalta was up 2.5% in New York at one stage even amid a global rout in the markets. Shire may announce a deal as soon as this week, Bloomberg News reported over the weekend, citing people familiar with the matter.

Reuters had reported before Christmas Shire had made a new acquisition offer for peer Baxalta that is roughly in line with the latter’s valuation expectations, making a deal in the coming weeks likely.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited